Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography

Anti-Cancer Drugs

Volumn 11, Issue 5, 2000, Pages 315-324

  Loos, Walter J ^a   De Bruijn, Peter ^a   Verweij, Jaap ^a   Sparreboom, Alex ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

9 Aminocamptothecin; HPLC; Irinotecan; Lurtotecan; SN 38; Topotecan

Indexed keywords

9 AMINOCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; IRINOTECAN; LACTONE; LURTOTECAN; TOPOTECAN;

DRUG DIFFUSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA TOPOISOMERASES, TYPE I; HUMANS; TOPOTECAN;

EID: 0033926690     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200006000-00001     Document Type: Review

References (42)

1. 1. Costin D, Potmesil M. Preclinical and clinical development of camptothecins. Adv Pharmacol 1994; 29B: 51-72.
2. 2. Creemers GJ, Lund B, Verweij J. Novel topoisomerase I inhibitors, topotecan and irinotecan. Cancer Treat Rev 1994; 20: 73-96.
3. 3. Gerrits CJH, Jonge MJA de, Schellens JHM, Stoter G, Verweij J. Topoisomerase-I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 1997; 76: 952-62.
4. 4. Herben VMM, Ten Bokkel Huinink WW, Schellens JHM, Beijnen JH. Clinical pharmaco-kinetics of camptothecin topoisomerase I inhibitors. Pharm World Sci 1998; 20: 161-72.
5. 5. Loos WJ, Verweij J, Gelderblom AJ, et al. Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20-S-camptothecin in humans. Anti-Cancer Drugs 1999; 10: 705-10.
6. 6. Burke TG, Munshi CB, Mi Z, Jiang Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 1995; 84: 518-9.
7. 7. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8.
8. 8. Rosing H, Man WY, Doyle E, Bult A, Beijnen JH. Bioanalytical liquid chromatographic method validation: a review of current practices and procedures (thesis). In: Bioanalytical chromatographic assays for new anticancer agents and their application in clinical pharmacologic research. Utrecht University 1998: 15-40.
9. 9. Beijnen JH, Smith BR, Keijer WJ, et al. High-performance liquid chromatographic analysis of the new antitumor drug SKF 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 1990; 8: 789-94.
10. 10. Loos WJ, Stoter G, Verweij J, Schellens JHM. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy-acid) in human plasma and urine. J Chromatogr B 1996; 678: 309-15.
11. 11. Rosing H, Van Zomeren DM, Doyle E, et al. Quantitation of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods. J Chromatogr B 1999; 727: 191-203.
12. 12. Rosing H, Doyle E, Davies BE, Beijnen JH. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chromatogr B 1995; 668: 107-15.
13. 13. Rosing H, Doyle E, Beijnen JH. The impact of column temperature in the high-performance liquid chromatographic analysis of topotecan in rat and dog plasma. J Pharm Biomed Anal 1996; 15: 279-86.
14. 14. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B 1997; 691: 161-71.
15. 15. Creemers GJ, Gerrits CJH, Schellens JHM, et al. Phase II and pharmacologic study of topotecan administered as a 21 days continuous infusion to patients with colorectal cancer. J Clin Oncol 1996; 14: 2540-5.
16. 16. Creemers GJ, Gerrits CJH, Eckard JR, et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21-days to adult patients with solid tumors. J Clin Oncol 1997; 15: 1087-93.
17. 17. Gerrits CJH, Burris H, Schellens JHM, et al. Oral topotecan given once or twice daily for ten days: a phase I and pharmacology study in adult patients with solid tumors. Clin Cancer Res 1998; 4: 1153-8.
18. 18. Gerrits CJH, Burris H, Schellens JHM, et al. Five days of oral topotecan (Hycamtin), a phase I and pharmacologic study in adult patients with solid tumors. Eur J Cancer 1998; 34: 1030-5.
19. 19. De Jonge MJA, Loos WJ, Gelderblom H, et al. Phase I and pharmacologic study of oral topotecan and intravenous cisplatin: sequence dependent hematologic side-effects. J Clin Oncol 2000; 18: 2104-15.
20. 20. Warner DL, Burke TG. Comparison of filter and tunable fluorescence detection for the HPLC simultaneous quantitation of lactone and carboxylate forms of topotecan in plasma. J Liq Chromatogr Rel Technol 1997; 20: 1523-37.
21. 21. Barilero I, Gandia D, Armand JP, et al. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. J Chromatogr B 1992; 575: 275-80.
22. 22. Rivory LP, Robert J. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivate irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr B 1994; 661: 133-41.
23. 23. Herben VMM, Mazee D, Van Zomeren DM, et al. Sensitive determinatiation of the carboxylate and lactone forms of the novel antitumour drug irinotecan and its active metabolite SN-38 in plasma by high-performance liquid chromatography. J Liq Chromatogr Rel Technol 1998; 21: 1541-58.
24. 24. Sumiyoshi H, Fujiwara Y, Ohune T, Yamaoka N, Tamura K, Yamakido M. High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. J Chromatogr B 1995; 670: 309-16.
25. 25. Kaneda N, Hosokawa Y, Yokokura T. Simultaneous determination of the lactone and carboxylate forms of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in rat plasma by high performance liquid chromatography. Biol Pharm Bull 1997; 20: 815-9.
26. 26. De Bruijn P, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr B 1997; 698: 277-85.
27. 27. Sparreboom A, De Bruijn P, De Jonge MJA, et al. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr B 1998; 712: 225-35.
28. 28. Sparreboom A, De Jonge MJA, De Bruijn P, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998; 4: 2747-54.
29. 29. Rivory LP, Findlay M, Clarke S, Bishop J. Trace analysis of SN-38 in human plasma by high-performance liquid chromatography. J Chromatogr B 1998; 714: 355-9.
30. 30. De Bruijn P, De Jonge MJA, Verweij J, et al. Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography. Anal Biochem 1999; 269: 174-8.
31. 31. Chollet DF, Goumaz L, Renard A, et al. Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivate CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography. J Chromatogr B 1998; 718: 163-75.
32. 32. Kurita A, Kaneda N. High-performance liquid chromatographic method for simultaneous determination of the camptothecin derivate irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. J Chromatogr B 1999; 724: 335-44.
33. 33 Ragot S, Marquet P, Lachatre F, et al. Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry. J Chromatogr B 1999; 736: 175-84.
34. 34. Gelderblom AJ, De Jonge MJA, Sparreboom A, Verweij J. Oral topoisomerase-I inhibitors in adult patients: present and future. Invest New Drugs 1999; 17: 401-15.
35. 35. Supko JG, Malspeis L. Liquid chromatographic analysis of 9-aminocamptothecin in plasma monitored by fluorescence induced upon postcolumn acidification. J Liq Chromatogr 1992; 15: 3261-83.
36. 36. Takimoto CH, Klercker RW, Dahut WL, et al. Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B 1994; 655: 97-104.
37. 37. Loos WF, Sparreboom A, Verweij J, Nooter K, Stoter G, Schellens JHM. Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by senstive high-performance liquid chromatography with fluorescence detection. J Chromatogr B 1997; 694: 435-41.
38. 38. Van Gijn R, Herben VMM, Hillebrand MJX, Ten Bokkel Huinink WW, Bult A, Beijnen JH. High-performance liquid chromatographic analysis of the investigational anticancer drug 9-aminocamptothecin, as the lactone form and as the total of the lactone and the hydroxycarboxylate forms, in micro-volumes of human plasma. J Pharm Biomed Anal 1998; 17: 1257-65.
39. 39. Emerson DL, Amirghahari N, Bendele R, et al. Enhanced in vivo amitumor efficacy of the liposome formulated topoisomerase I inhibitor Lurtotecan. Proc Am Ass Cancer Res 1999; 40: 151.
40. 40. Stafford CG, Claire RL St. High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211 ) in plasma. J Chromatogr B 1995; 663: 119-26.
41. 41. Selinger K, Smith G, Depee S, Aureche C. Determination of GI147211 in human blood by HPLC with fluorescence detection. J Pharm Biomed Anal 1995; 13: 1521-30.
42. 42. Loos WJ, Kehrer D, Brouwer E, et al. Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography. J Chromatogr B 2000; 738: 155-63.